Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir,

Slides:

Advertisements

Similar presentations

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Advertisements

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Leptin receptor variant in women with polycystic ovary syndrome

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome Li Chen, M.S., Wen.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome Silvia Ajossa, M.D., Stefano Guerriero, M.D.,

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome Elisabeth Lerchbaum,

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives George Mastorakos,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

The spectrum of androgen excess disorders

Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot.

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome Kelly Stamets,

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome Héctor F. Escobar-Morreale,

Evolutionary determinants of polycystic ovary syndrome: part 1

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome Macarena Alpañés, M.D., Manuel.

Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women.

Increased secretion of amylin in women with polycystic ovary syndrome

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic.

Imran Pirwany, MD, Togas Tulandi, MD Fertility and Sterility

Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome Carlos Moran, M.D.,

Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation.

Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Serum resistin levels in women with polycystic ovary syndrome

Decreased levels of interleukin-18 in peritoneal fluid but not in serum of patients with endometriosis Xinmei Zhang, M.D., Jun Lin, M.D., Yuli Qian,

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin Elsy Velázquez M, M.D.,

Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate–resistant polycystic ovary.

Paolo Moghetti, M.D. Fertility and Sterility

Are patients with idiopathic hirsutism (IH) insulin resistant

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Anna Maria Fulghesu, M. D. , Mario Ciampelli, M. D. , Giuseppe Muzj, M

Increased total and phosphorylated glycogen synthase kinase-3 (GSK-3) in the adipocytes of patients with the polycystic ovary syndrome (PCOS) W.Y. Chang,

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular.

Enrico Carmina, M.D., Rogerio A Lobo, M.D. Fertility and Sterility

Presentation transcript:

Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir, M.D., Babur Kaleli, M.D. Fertility and Sterility Volume 79, Issue 6, Pages 1358-1364 (June 2003) DOI: 10.1016/S0015-0282(03)00265-6

FIGURE 1 Mean (±SD) serum glucose levels during a 75-g oral glucose tolerance test in women with the polycystic ovary syndrome (PCOS) and controls.*P<.05. Yildirim. Visceral fat and metabolic disorders in PCOSFertil Steril 2003. Fertility and Sterility 2003 79, 1358-1364DOI: (10.1016/S0015-0282(03)00265-6)

FIGURE 2 Mean (±SD) serum insulin levels during a 75-g oral glucose tolerance test in women with the polycystic ovary syndrome (PCOS) and controls. All comparisons were statistically significant. Yildirim. Visceral fat and metabolic disorders in PCOS.Fertil Steril 2003. Fertility and Sterility 2003 79, 1358-1364DOI: (10.1016/S0015-0282(03)00265-6)